The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes

The incretin effect is known to be decreased in type 2 diabetes. However, there are limited data on the incretin effect in non‐Caucasian subjects. Because Asian patients with type 2 diabetes are characterized by decreased insulin secretion, this study set out to examine the incretin effect in Korean subjects with normal glucose tolerance (NGT) or type 2 diabetes.

[1]  J. Holst,et al.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? , 2010, Diabetologia.

[2]  I. Täljedal.  On insulin secretion , 1981, Diabetologia.

[3]  R. Rizza,et al.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[4]  M. Marmot,et al.  Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians , 1991, The Lancet.

[5]  M. T. Brennan,et al.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. , 1967, The Journal of clinical investigation.

[6]  Yup Kang,et al.  Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes. , 2010, Diabetes research and clinical practice.

[7]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[8]  Andrea Mari,et al.  Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients , 2008, Diabetes.

[9]  J. Holst,et al.  Reduced Incretin Effect in Type 2 Diabetes - Cause or Consequence of the Diabetic State? Received for publication 23 January 2007 and accepted in revised form 3 May 2007. , 2007 .

[10]  S. Joshi.  Metabolic syndrome--emerging clusters of the Indian phenotype. , 2003, The Journal of the Association of Physicians of India.

[11]  Anoop Misra,et al.  Obesity and the metabolic syndrome in developing countries. , 2008, The Journal of clinical endocrinology and metabolism.

[12]  P Zimmet,et al.  Ethnic comparisons of the cross‐sectional relationships between measures of body size with diabetes and hypertension , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[13]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[14]  Mi Yeon Kim,et al.  Glucose-Dependent Insulinotropic Peptide Level Is Associated with the Development of Type 2 Diabetes Mellitus , 2016, Endocrinology and metabolism.

[15]  J. Holst,et al.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus , 2007, Diabetologia.

[16]  R. Bergman,et al.  Validation of methods for measurement of insulin secretion in humans in vivo. , 2000, Diabetes.

[17]  Y. Seino,et al.  Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. , 2004, Diabetes research and clinical practice.

[18]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[19]  J. Holst,et al.  Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls , 2010, Journal of diabetes investigation.

[20]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[21]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[22]  F. Katsukawa,et al.  Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis , 2003, Acta Diabetologica.

[23]  J. Holst,et al.  The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. , 2011, American journal of physiology. Endocrinology and metabolism.

[24]  James J. Cai,et al.  Adaptive selection of an incretin gene in Eurasian populations. , 2011, Genome research.

[25]  J. Wishart,et al.  Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[26]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[27]  Akihisa Imagawa,et al.  Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. , 2010, Biochemical and biophysical research communications.

[28]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[29]  L. Groop,et al.  Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. , 2000, Diabetes.

[30]  M. Nauck,et al.  Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? , 2010, Diabetes.

[31]  J. Holst,et al.  Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. , 2010, American journal of physiology. Endocrinology and metabolism.

[32]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[33]  Henrik Vestergaard,et al.  Impaired regulation of the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[34]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.